At the time of writing, Cyclacel Pharmaceuticals Inc [CYCC] stock is trading at $1.01, up 2.02%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CYCC shares have gain 27.01% over the last week, with a monthly amount drifted -3.35%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On September 07, 2018, Ladenburg Thalmann initiated with a Buy rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $5 on October 16, 2015. Roth Capital initiated its recommendation with a Buy and recommended $7 as its price target on February 04, 2010. In a note dated August 12, 2008, Piper Jaffray initiated an Buy rating and provided a target price of $5 on this stock.
For the past year, the stock price of Cyclacel Pharmaceuticals Inc fluctuated between $0.75 and $11.34. Cyclacel Pharmaceuticals Inc [NASDAQ: CYCC] shares were valued at $1.01 at the most recent close of the market.
Analyzing the CYCC fundamentals
According to Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC], the company’s sales were 0.08M for trailing twelve months, which represents an -98.93% plunge. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -303.99%, Pretax Profit Margin comes in at -305.95%, and Net Profit Margin reading is -219.64%. To continue investigating profitability, this company’s Return on Assets is posted at -2.15, Equity is -18.74 and Total Capital is -24.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9100 points at the first support level, and at 0.8100 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1500, and for the 2nd resistance point, it is at 1.2900.
Ratios To Look Out For
It is important to note that Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] has a current ratio of 1.07. Also, the Quick Ratio is 1.07, while the Cash Ratio stands at 0.83. Considering the valuation of this stock, the price to sales ratio is 27.14, the price to book ratio is 1.83.
Transactions by insiders
Recent insider trading involved McBarron Paul, that happened on Dec 21 ’23 when 1886.0 shares were purchased. President and CEO, Rombotis Spiro George completed a deal on Dec 21 ’23 to buy 6070.0 shares.
